Icosapent Ethyl
Amarin Pharmaceutical
[]
#respectepa shows trend for benefit for #epa (no mineral oil control) with 21% reduction in primary outcome, borderline significance. trial may have been underpowered. increase in afib &amp; gi sz but not bleeding. #aha22 
Johns Hopkins Medicine. Associate Professor, Cardiology. Co-Editor in Chief @AJPCardio. #WomenHeartHealth #CardioObstetrics #cvPrev #echofirst She/her #BeKind